Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SL1002 in Knee Pain Associated With Osteoarthritis
NCT07226258Phase 3Active, not recruiting
- Sponsor
- Saol Therapeutics
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of SL-1002 in osteoarthritis (OA), sponsored by Saol Therapeutics. Started Nov 2025; status: active, not recruiting.
02
Drugs
SL-1002
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07226258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226258.